{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:22:31Z","timestamp":1789734151610,"version":"4.0.1"},"reference-count":15,"publisher":"Tohoku University Medical Press","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2022]]},"DOI":"10.1620\/tjem.256.119","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T22:08:21Z","timestamp":1644962901000},"page":"119-125","source":"Crossref","is-referenced-by-count":3,"title":["Immunohistopathological Analysis of Extramedullary Hematopoiesis and Angiogenesis of Spleen in a Case of Primary Myelofibrosis with Huge Splenomegaly"],"prefix":"10.1620","volume":"256","author":[{"given":"Noriaki","family":"Kawano","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Hematology, Saiseikai Fukuoka General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuro","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kitanaka","sequence":"additional","affiliation":[{"name":"Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Shide","sequence":"additional","affiliation":[{"name":"Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kousuke","family":"Marutsuka","sequence":"additional","affiliation":[{"name":"Department of Pathology, Miyazaki Prefectural Miyazaki Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Ohshima","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Shimoda","sequence":"additional","affiliation":[{"name":"Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"622","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Barbui, T., Thiele, J., Gisslinger, H., Kvasnicka, H.M., Vannucchi, A.M., Guglielmelli, P., Orazi, A. &amp; Tefferi, A.(2018)  The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.  <i>Blood Cancer J<\/i>., 8, 15.","DOI":"10.1038\/s41408-018-0054-y"},{"key":"2","unstructured":"Barosi, G., Rosti, V., Massa, M., Viarengo, G.L., Pecci, A., Necchi, V., Ramaioli, I., Campanelli, R., Marchetti, M., Bazzan, M. &amp; Magrini, U.(2004)  Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia.  <i>Br. J. Haematol<\/i>., 124, 618-625."},{"key":"3","doi-asserted-by":"crossref","unstructured":"Garmezy, B., Schaefer, J.K., Mercer, J. &amp; Talpaz, M.(2021)  A provider\u2019s guide to primary myelofibrosis: pathophysiology, diagnosis, and management.  <i>Blood Rev<\/i>., 45, 100691.","DOI":"10.1016\/j.blre.2020.100691"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Kawano, S., Kato, J., Kawano, N., Yoshimura, Y., Masuyama, H., Fukunaga, T., Shimao, Y., Mihara, K., Ueda, A., Toyoda, K., Imamura, T. &amp; Kitamura, K.(2012)  Sarcoidosis manifesting as cardiac sarcoidosis and massive splenomegaly.  <i>Intern. Med<\/i>., 51, 65-69.","DOI":"10.2169\/internalmedicine.51.5247"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Kitanaka, A., Takenaka, K., Shide, K., Miyamoto, T., Kondo, T., Ozawa, K., Kurokawa, M., Akashi, K. &amp; Shimoda, K.(2016)  Splenic irradiation provides transient palliation for symptomatic splenomegaly associated with primary myelofibrosis: a report on 14 patients.  <i>Int. J. Hematol<\/i>., 103, 423-428.","DOI":"10.1007\/s12185-016-1940-3"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Klco, J.M., Vij, R., Kreisel, F.H., Hassan, A. &amp; Frater, J.L.(2010)  Molecular pathology of myeloproliferative neoplasms.  <i>Am. J. Clin. Pathol<\/i>., 133, 602-615.","DOI":"10.1309\/AJCPPPZ1WFVGNE4A"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Mesa, R.A., Li, C.Y., Schroeder, G. &amp; Tefferi, A.(2001)  Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia.  <i>Blood<\/i>, 97, 3665-3667.","DOI":"10.1182\/blood.V97.11.3665"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Ozono, Y., Shide, K., Kameda, T., Kamiunten, A., Tahira, Y., Sekine, M., Akizuki, K., Nakamura, K., Iwakiri, H., Sueta, M., Hidaka, T., Kubuki, Y., Yamamoto, S., Hasuike, S., Sawaguchi, A.,  et al.(2021)  Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice.  <i>Leukemia<\/i>, 35, 454-467.","DOI":"10.1038\/s41375-020-0880-3"},{"key":"9","doi-asserted-by":"publisher","unstructured":"Saito, N., Yamauchi, T., Kawano, N., Ono, R., Yoshida, S., Miyamoto, T., Kamimura, T., Shultz, L.D., Saito, Y., Takenaka, K., Shimoda, K., Harada, M., Akashi, K. &amp; Ishikawa, F.(2021). Circulating CD34+CD38- cells of primary myelofibrosis patients contribute to myeloid dominant hematopoiesis and bone marrow fibrosis in immunodeficient mice. <i> Int. J. Hematol.<\/i>, doi: 10.1007\/s12185-021-03239-y. [Epub ahead of print].","DOI":"10.1007\/s12185-021-03239-y"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Santos, F.P., Tam, C.S., Kantarjian, H., Cortes, J., Thomas, D., Pollock, R. &amp; Verstovsek, S.(2014)  Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation.  <i>Leuk. Lymphoma<\/i>, 55, 121-127.","DOI":"10.3109\/10428194.2013.794269"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Shimizu-Kohno, K., Kimura, Y., Kiyasu, J., Miyoshi, H., Yoshida, M., Ichikawa, R., Niino, D. &amp; Ohshima, K.(2012)  Malignant lymphoma of the spleen in Japan: a clinicopathological analysis of 115 cases.  <i>Pathol. Int<\/i>., 62, 577-582.","DOI":"10.1111\/j.1440-1827.2012.02844.x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Shimoda, K., Takahashi, N., Kirito, K., Iriyama, N., Kawaguchi, T. &amp; Kizaki, M.(2020)  JSH practical guidelines for hematological malignancies, 2018: I. Leukemia-4. Chronic myeloid leukemia (CML)\/myeloproliferative neoplasms (MPN).  <i>Int. J. Hematol<\/i>., 112, 268-291.","DOI":"10.1007\/s12185-020-02964-0"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Song, M.K., Chung, J.S., Lim, S.N., Lee, G.W., Lee, S.M., Lee, N.K., Choi, J.C. &amp; Oh, S.Y.(2016)  Usefulness of spleen volume measured by computed tomography for predicting clinical outcome in primary myelofibrosis.  <i>Int. J. Hematol<\/i>., 104, 476-484.","DOI":"10.1007\/s12185-016-2050-y"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Vannucchi, A.M., Kantarjian, H.M., Kiladjian, J.J., Gotlib, J., Cervantes, F., Mesa, R.A., Sarlis, N.J., Peng, W., Sandor, V., Gopalakrishna, P., Hmissi, A., Stalbovskaya, V., Gupta, V., Harrison, C., Verstovsek, S.,  et al.(2015)  A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.  <i>Haematologica<\/i>, 100, 1139-1145.","DOI":"10.3324\/haematol.2014.119545"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Wang, X., Prakash, S., Lu, M., Tripodi, J., Ye, F., Najfeld, V., Li, Y., Schwartz, M., Weinberg, R., Roda, P., Orazi, A. &amp; Hoffman, R.(2012)  Spleens of myelofibrosis patients contain malignant hematopoietic stem cells.  <i>J. Clin. Invest<\/i>., 122, 3888-3899.","DOI":"10.1172\/JCI64397"}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/256\/2\/256_119\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T04:26:31Z","timestamp":1645244791000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/256\/2\/256_119\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.256.119","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]}}}